JTCR016: Phase I/II data

Top-line data from 3 patients with WT1-expressing stage III or IV NSCLC or mesothelioma in an open-label, dose-escalation, U.S. Phase I/II trial showed that a single IV dose of JTCR016 led to 1 partia...